Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1

Conditions

Lymphoma, Large B-Cell, Diffuse 413Lymphoma 401Lymphoma, Non-Hodgkin 337Leukemia, Lymphocytic, Chronic, B-Cell 302Lymphoma, Follicular 295Lymphoma, Mantle-Cell 225Lymphoma, B-Cell, Marginal Zone 159Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 83Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Dendritic Cell Sarcoma, Interdigitating 22Hematologic Neoplasms 21Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Lymphoproliferative Disorders 12Hematologic Diseases 12

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Melanoma × Rituximab × Clear all
NCT03719131 2025-04-22

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Emory University

Phase 2 Active not recruiting
15 enrolled 10 charts
Dermatologic

Melanoma

NCT01307267 2020-03-17

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Pfizer

Phase 1 Completed
190 enrolled 65 charts
DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Lymphoma, Large B-Cell, Diffuse

NCT02142335 2014-05-20

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

California Cancer Assocaties for Research & Excellence

Phase 2 Unknown
17 enrolled
Dermatologic

Melanoma

NCT01032122 2013-04-25

Rituximab in Metastatic Melanoma

Medical University of Vienna

Phase 1 Terminated
9 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡